

## Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae

Jessica Lizbeth Raygoza Robles<sup>1</sup>, Felipe Alarcón Estrada<sup>2</sup>, Cesar Monroy Rojas<sup>2</sup>, Jenifer Pamela Sierra Alaniz<sup>1</sup>

<sup>1</sup>Universidad Cuauhtémoc campus Aguascalientes. Aguascalientes, Mexico.

<sup>2</sup>Universidad Anáhuac México Campus Norte. Mexico.

### ABSTRACT

**ABSTRACT:** Lyme disease, a multisystem infectious process instigated by the spirochete *Borrelia burgdorferi sensu lato* complex, remains a formidable clinical entity due to its protean systemic manifestations. Cardiac involvement, termed Lyme carditis, represents an uncommon yet potentially critical complication of disseminated early infection, characterized by spirochetal infiltration of cardiac tissues precipitating a spectrum of conduction abnormalities and myocardial inflammation. This article synthesizes contemporary understanding of the molecular pathogenesis underlying *Borrelia*-mediated cardiotropism, focusing on post-infectious inflammatory cascades and potential persistent immunogenic stimuli. Clinical presentation is critically examined, emphasizing the diagnostic challenges posed by variable symptomology ranging from subclinical conduction delays to high-grade atrioventricular block and, rarely, myopericarditis. The discourse advances to a nuanced analysis of current therapeutic strategies, juxtaposing guideline-recommended antibiotic regimens against complex presentations necessitating advanced cardiac interventions, such as temporary pacing. Furthermore, the manuscript engages with emergent debates concerning post-treatment Lyme disease syndrome (PTLDS) and its potential cardiological correlates, a domain requiring further delineation. By integrating recent epidemiological data and advanced diagnostic modalities, including serological interpretation and novel imaging techniques, this review aims to provide a comprehensive, evidence-based framework for the recognition and management of this intriguing cardioneuropathic syndrome, thereby mitigating the risk of long-term cardiac morbidity.

**KEYWORDS:** Lyme carditis; *Borrelia burgdorferi*; atrioventricular block; infectious myocarditis; cardiac conduction system disease; post-treatment Lyme disease syndrome; antibiotic therapy; cardiac pacing; molecular mimicry; spirochetal persistence.

### ARTICLE DETAILS

**Published On:**  
**08 January 2026**

**Available on:**  
**<https://ijmscrs.com>**

### INTRODUCTION

The epidemiological trajectory of Lyme borreliosis continues to exhibit an upward trend in endemic regions, reinforcing its status as a significant vector-borne zoonosis with considerable public health implications. While early localized infection typically manifests with dermatological findings, hematogenous dissemination can lead to involvement of neurological, articular, and cardiac structures. Cardiac manifestations, first formally described in the latter half of the twentieth century, complicate an estimated subset of untreated disseminated cases, presenting a unique

intersection of infectious disease and cardiology. The pathophysiological mechanisms are multifactorial, involving direct spirochetal invasion of the myocardium and conductive tissues, coupled with a pronounced host inflammatory response. This inflammatory milieu is thought to be perpetuated by both innate and adaptive immune reactions, with recent investigations implicating mechanisms such as molecular mimicry and biofilm-like persistence in the perpetuation of symptoms beyond standard antimicrobial therapy. The clinical hallmark of Lyme carditis is a fluctuating, often high-grade, atrioventricular block, which

# Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae

may evolve rapidly; however, presentations can be subtler, encompassing palpitations, lightheadedness, or generalized fatigue, often obscuring the underlying infectious etiology.<sup>1,2,3</sup>

Diagnostic confirmation hinges upon a high clinical index of suspicion, supportive serological testing via standardized two-tiered protocols, and characteristic electrocardiographic findings, occasionally supplemented by advanced cardiac imaging to assess for concomitant myocardial inflammation. Management fundamentally centers on appropriate antibiotic therapy, with intravenous ceftriaxone often indicated for hospitalized patients with significant conduction disease, alongside judicious cardiac monitoring for potential progression requiring temporary pacing support. Despite generally favorable outcomes with prompt treatment, lingering questions regarding chronic electrical instability or inflammatory cardiomyopathy in a minority of patients persist, fueled by ongoing research into the spirochete's ability to evade host defenses and incite prolonged immunological perturbation. This introduction sets the stage for a detailed exploration of these contemporary clinical and scientific challenges, drawing upon recent scholarly work to frame the current understanding and unanswered questions surrounding this distinct cardioneuropathic entity.<sup>2,3</sup>

## Background

The historical and clinical antecedents of Lyme carditis are deeply intertwined with the broader recognition of Lyme borreliosis as a distinct clinical entity. Initial medical descriptions of a cardiac complication associated with what would later be termed Lyme disease emerged from Europe in the early 20th century, with reports linking erythema migrans-like rashes to concurrent cardiac arrhythmias. However, it was the systematic investigation of the clustering of juvenile arthritis in Lyme, Connecticut, in the 1970s that catalyzed the modern understanding of the disease's multisystem potential. Within this framework, cardiac manifestations were soon identified as a significant feature of disseminated infection. Early clinical case series from endemic regions in the United States meticulously documented the predilection of *Borrelia burgdorferi* for the cardiac conduction system, establishing the characteristic presentation of fluctuating atrioventricular block, often in young, otherwise healthy individuals. These foundational observations were pivotal in classifying Lyme carditis as a distinct clinical syndrome within the spectrum of disseminated borreliosis.<sup>3,4,5</sup>

Pathogenetically, the antecedents of current understanding stem from histopathological analyses of myocardial tissue from fatal cases, which demonstrated the presence of spirochetes within the myocardium and conduction system, accompanied by a robust lymphocytic and plasmacytic infiltrate. This direct microbiological evidence solidified the premise of direct microbial invasion as a primary driver of pathology, distinguishing it from purely post-infectious or

reactive carditis. Concurrently, the development and refinement of serological assays, from indirect immunofluorescence to the contemporary two-tiered testing algorithm employing enzyme immunoassay and Western blot, provided the necessary tools for corroborating clinical suspicion. The historical reliance on this serological paradigm, while instrumental, has also bequeathed ongoing challenges, particularly regarding sensitivity in early infection and the interpretation of seropositivity in endemic areas, a diagnostic nuance that continues to complicate case ascertainment.<sup>4,5,6</sup>

Therapeutically, antecedent management strategies evolved from early empirical use of penicillin and tetracycline to the current evidence-based guidelines recommending targeted antibiotic regimens, most notably doxycycline or ceftriaxone, with duration contingent upon disease severity. The historical observation that high-grade heart block often resolves with antimicrobial therapy alone, frequently obviating the need for permanent pacing, remains a cornerstone of management and a key differential point from other etiologies of conduction disease. However, recent scholarly discourse has complicated this historically straightforward narrative. Contemporary investigations are increasingly focused on the immunological sequelae that may outlast microbiological clearance, engaging with concepts such as persistent inflammatory responses and potential antigenic debris. Furthermore, advanced cardiac imaging modalities, including cardiac magnetic resonance with late gadolinium enhancement, have begun to reveal subtle myocardial involvement previously undetectable, suggesting that the historical clinical spectrum of the disease may have been underspecified. These evolving perspectives, informed by a more sophisticated appreciation of host-pathogen interaction, frame the current investigative landscape, moving beyond a model of simple infection and eradication to one encompassing complex, sometimes prolonged, immunopathological processes that define the modern understanding of Lyme carditis and its potential long-term implications.<sup>4,5,6</sup>

## Clinical Manifestations of Lyme Carditis: A Spectrum of Cardioneuropathic Presentations

The clinical presentation of Lyme carditis is notoriously heterogeneous, ranging from subclinical electrical disturbances to life-threatening hemodynamic compromise, a variability that often precipitates diagnostic ambiguity. The quintessential and most frequently documented manifestation is acute-onset impairment of the cardiac conduction system, predominantly affecting the atrioventricular (AV) node. This typically manifests as a fluctuating, often rapidly progressive, degree of AV block. Patients may present with first-degree AV block, often an incidental finding, which can evolve unpredictably into higher-grade Mobitz type I (Wenckebach) or, more characteristically, complete heart block. The pathognomonic feature of this conduction disease is its labile nature; profound bradycardia may alternate with periods of

## **Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae**

normal conduction over hours or days, a reflection of the intense but variable inflammatory edema surrounding the conduction pathways rather than irreversible fibrosis. This lability is a critical differentiator from atherosclerotic or degenerative conduction disease. Symptomatology directly correlates with the severity of bradycardia and the resultant decrease in cardiac output. Common reports include pre-syncope or frank syncope, profound lightheadedness, palpitations perceived as skipped beats or pauses, dyspnea on exertion from an inadequate chronotropic response, and generalized fatigue or exercise intolerance. Notably, chest discomfort, while not a cardinal feature, can be present and may be described as a vague, pressure-like sensation, possibly attributable to concomitant myocarditis or pericardial inflammation.<sup>5,6,7</sup>

Beyond conduction abnormalities, direct spirochetal invasion can incite a more generalized myocardial inflammatory response, termed Lyme myocarditis. This condition may present with symptoms congruent with heart failure, including exertional dyspnea, orthopnea, and peripheral edema, though overt cardiogenic shock is exceedingly rare. Physical examination may reveal a pericardial friction rub if there is pericardial involvement, signs of congestive heart failure, or simply the auscultatory findings of bradyarrhythmias. Palpation might not reveal cardiomegaly in the acute phase. A critical and often underappreciated aspect of the clinical presentation is the frequent coexistence of systemic symptoms indicative of disseminated borreliosis. A significant proportion of patients will report or exhibit concomitant signs such as migratory arthralgias, myalgias, persistent headache, or peripheral neuropathy. Crucially, a history of an erythema migrans rash, which may have resolved weeks prior to cardiac symptoms, is a pivotal epidemiological clue, though its absence does not exclude the diagnosis. The temporal relationship is key; carditis typically arises within weeks to several months following the initial tick bite and infection, placing it within the early disseminated stage of Lyme disease.<sup>6,7,8</sup>

The clinical picture is further complicated by the potential for subtle or atypical presentations. Some individuals may experience only isolated palpitations or mild dizziness, with electrocardiographic monitoring revealing sporadic, non-sustained ventricular ectopy or brief episodes of sinus pause, findings that can be mistakenly attributed to benign conditions. Furthermore, emerging clinical data suggest that a subset of patients, even after appropriate antibiotic therapy for documented Lyme carditis, may report persistent, non-specific symptoms such as exercise-induced palpitations or autonomic dysfunction, sparking investigative interest into potential long-term electrical remodeling or low-grade persistent inflammatory states. Therefore, a high clinical index of suspicion is paramount, particularly in an endemic region when evaluating a young, otherwise healthy individual with new-onset conduction disease or unexplained syncope,

manditating a thorough inquiry into potential tick exposure and a systematic integration of cardiac findings within the broader context of possible multisystem borreliosis.<sup>9,10,11</sup>

### **Diagnostic**

The diagnostic confirmation of Lyme carditis necessitates a syncretic approach, weaving together clinical acumen, targeted serological investigation, and advanced cardiac assessment to distinguish it from the broad differential of acute carditis and conduction disease. The diagnostic pathway is fundamentally initiated by a high index of suspicion, which is paramount in endemic geographical regions or in patients with a plausible epidemiological history of tick exposure. The cornerstone of laboratory diagnosis remains the two-tiered serological testing protocol as recommended by the Centers for Disease Control and Prevention, which commences with a sensitive enzyme immunoassay (EIA) or immunofluorescence assay (IFA). A positive or equivocal initial test is reflexively followed by supplemental testing with standardized Western immunoblot, seeking the presence of specific IgM and IgG antibodies against *Borrelia burgdorferi*. It is critical to interpret these results within the appropriate clinical context, as IgM antibodies may persist for months and IgG seropositivity can indicate remote, resolved infection, particularly in highly endemic areas. Therefore, serology confirms exposure but does not, in isolation, temporally link the infection to active cardiac pathology. In cases of high clinical suspicion with negative or indeterminate early serology, convalescent serological testing after a two-to-four-week interval is often indispensable, as the humoral immune response requires time to mature.<sup>12,13</sup>

Concurrent with serological evaluation, comprehensive cardiac assessment is imperative. The 12-lead surface electrocardiogram serves as the primary and most accessible tool, capable of revealing the spectrum of conduction abnormalities characteristic of the disease, from a prolonged PR interval to complete heart block. Given the notorious lability of the conduction defect, continuous ambulatory electrocardiographic monitoring, via Holter monitor or an inpatient telemetry system, is frequently required to capture the fluctuating nature of the block and to correlate symptoms with arrhythmic events. This monitoring also aids in assessing the response to antimicrobial therapy, as improvement in AV conduction is a strong confirmatory sign. Advanced cardiac imaging has assumed an increasingly prominent role in the diagnostic algorithm. Transthoracic echocardiography is routinely performed to evaluate for associated myocardial dysfunction, pericardial effusion, or regional wall motion abnormalities suggestive of myocarditis, though its findings are often normal in isolated conduction system disease. More definitively, cardiac magnetic resonance imaging with late gadolinium enhancement sequences has emerged as a powerful modality for detecting myocardial inflammation and edema, offering

## **Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae**

tissue characterization that can support the diagnosis of active myocarditis and help gauge the extent of involvement.<sup>13</sup>

A meticulous integration of these diagnostic strands is essential. The presence of a compatible clinical syndrome, supportive serological evidence of recent or current *Borrelia* infection, and demonstrable cardiac involvement—typically a conduction disturbance—establishes the diagnosis. In ambiguous cases, or when a competing etiology such as cardiac sarcoidosis or giant cell myocarditis is a consideration, more invasive procedures may be contemplated. Endomyocardial biopsy, while historically revealing lymphocytic infiltrates and, in rare instances, spirochetes on specialized staining, is limited by its invasiveness and sampling error and is not recommended for routine diagnosis. Contemporary diagnostic paradigms emphasize the elimination of other causes. Consequently, a thorough workup often includes assessment for viral pathogens, autoimmune serologies, and other conditions that can mimic this presentation. Ultimately, the diagnosis of Lyme carditis rests on a probabilistic framework, where epidemiological context, evolving serological profiles, characteristic and often labile electrocardiographic findings, and a prompt clinical response to appropriate antibiotic therapy collectively converge to confirm the pathogenic role of *Borrelia burgdorferi* in the observed cardiac pathology.<sup>13,14</sup>

### **Pathophysiology of Lyme Carditis: Molecular Mechanisms of Spirochetal Cardiotropism and Host Inflammatory Sequelae**

The pathophysiological cascade underlying Lyme carditis represents a complex interplay between direct microbial invasion and the subsequent host-derived inflammatory response, a process that begins with the dissemination of *Borrelia burgdorferi* sensu lato spirochetes from the initial dermal inoculation site. Following hematogenous spread, a critical and incompletely understood tropism guides a subset of spirochetes to cardiac tissues, with a particular affinity for the conductive system, the myocardium, and the pericardium. This cardiotropism is not stochastic but is likely mediated by specific molecular interactions. Research indicates that *Borrelia* surface lipoproteins, such as OspA and OspC, along with other adhesion molecules like decorin-binding proteins, facilitate binding to host extracellular matrix components and cellular integrins present within the cardiac microenvironment. Upon localization, the spirochetes do not typically invade cardiomyocytes in great numbers but rather reside within the interstitial connective tissue, pericardium, and importantly, within the rich collagenous matrix surrounding the atrioventricular node and the bundle of His. The primary insult stems from the local presence of these spirochetes and their potent immunogenic components, particularly membrane-associated lipoproteins. These molecules are recognized by toll-like receptors, predominantly TLR1 and TLR2 heterodimers, on resident

cardiac macrophages, dendritic cells, and endothelial cells. This recognition triggers a robust innate immune response, characterized by the NF- $\kappa$ B-mediated production of pro-inflammatory cytokines and chemokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- $\alpha$ ), and IL-1 $\beta$ . This cytokine milieu serves as a chemotactic signal, orchestrating a substantial transmigration of adaptive immune cells into the affected cardiac tissues. The resulting histopathological hallmark is a dense lymphohistiocytic infiltrate, rich in T-lymphocytes and plasma cells, which creates edema, cellular disruption, and functional interference within the delicate architecture of the conduction system. The fluctuating nature of the characteristic atrioventricular block is a direct clinical correlate of this inflammatory edema, which temporarily disrupts electrical impulse propagation without causing immediate, irreversible necrosis.<sup>14,15</sup>

Simultaneously, the pathophysiology is compounded by potential autoimmune mechanisms, notably molecular mimicry. Structural similarities between certain *Borrelia burgdorferi* antigens, such as flagellin, and human proteins, including those within cardiac myosin, may lead to the generation of cross-reactive antibodies and autoreactive T-cell clones. This bystander activation can perpetuate myocardial inflammation and dysfunction even after microbiological clearance, a concept that provides a plausible framework for understanding persistent subjective symptoms in some patients and the occasional observation of a more protracted clinical course. Furthermore, emerging investigations into potential spirochetal persistence, facilitated by biofilm-like aggregates or altered morphological forms, suggest a model wherein a low-level chronic antigenic stimulus could drive a smoldering inflammatory response, contributing to long-term sequelae. The resultant clinical syndrome—whether acute high-grade block, subtle myopericarditis, or post-infectious dysautonomia—thus emerges not from a singular mechanism, but from a dynamic and often individualized confluence of direct microbial cytotoxicity, acute immunoinflammatory injury, and potential autoimmune dysregulation, all unfolding within the unique and electrically sensitive milieu of the human heart.<sup>14,15</sup>

### **Management**

The therapeutic management of Lyme carditis is predicated on a dual-strategy paradigm that integrates targeted antimicrobial pharmacotherapy with vigilant cardiac supportive care, the urgency and intensity of which are dictated by the severity of conduction system involvement and overall clinical stability. The foundational pharmacological intervention is the prompt administration of appropriate antibiotic regimens aimed at eradicating the causative *Borrelia burgdorferi* spirochetes from cardiac tissues. For outpatient management of mild to moderate manifestations, such as first-degree or asymptomatic second-degree atrioventricular (AV) block, the current standard of

## **Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae**

care involves a 14- to 21-day course of oral doxycycline, a bacteriostatic agent with excellent tissue penetration and proven efficacy against the spirochete. In cases where doxycycline is contraindicated, alternative oral regimens such as amoxicillin or cefuroxime axetil are employed. However, for patients exhibiting more severe cardiac involvement, including symptomatic high-grade second-degree or complete heart block, or any evidence of concomitant myopericarditis with ventricular dysfunction, hospitalization is mandatory. In this inpatient setting, the consensus guidelines strongly recommend the initiation of intravenous antibiotic therapy, typically with ceftriaxone for a duration of 14 to 21 days, to ensure reliable and rapid achievement of bactericidal concentrations within the inflamed cardiac interstitium.<sup>13,14,15</sup>

Concurrent with antimicrobial therapy, meticulous cardiac monitoring and supportive interventions constitute an equally critical pillar of management. Given the propensity for rapid progression and fluctuation of AV conduction abnormalities, continuous telemetric monitoring in a cardiac care unit or step-down setting is non-negotiable for patients with anything beyond trivial first-degree block. The primary objective of this surveillance is to detect progression to higher-grade block that may precipitate hemodynamic compromise. The management of significant bradycardia follows established advanced cardiac life support principles. The judicious use of intravenous atropine may provide transient improvement in nodal conduction, but its efficacy is often limited and unpredictable in this inflammatory context. The definitive supportive intervention for patients with symptomatic high-grade AV block is the timely placement of a temporary transvenous pacemaker. This intervention is not curative but serves as a vital bridge, maintaining adequate cardiac output and preventing syncope or sudden cardiac death while antibiotic therapy mitigates the underlying inflammatory edema. It is a cardinal principle in Lyme carditis that, unlike degenerative conduction disease, the need for permanent pacemaker implantation is exceedingly rare, as the conduction disturbance is almost uniformly reversible with treatment of the infection. Therefore, pacemaker implantation should be assiduously avoided in the acute phase unless conduction abnormalities persist for weeks after the completion of appropriate antibiotic therapy.<sup>14,15</sup>

The therapeutic course also necessitates a nuanced approach to adjunctive therapies. The role of corticosteroids remains controversial and is not supported by robust clinical trial evidence. Their use is generally discouraged in routine management due to theoretical concerns of immunosuppression potentially impairing spirochetal clearance, though they may be considered in exceptional, refractory cases with severe myocarditis unresponsive to antibiotics alone, following infectious disease consultation.<sup>14,15</sup>

Furthermore, the post-therapeutic phase requires careful follow-up. Serial electrocardiograms are warranted to document the expected resolution of conduction delays, which often begins within days of initiating antibiotics but may take weeks to fully normalize. Patient education regarding the completion of the full antibiotic course, even after symptomatic improvement, is paramount to prevent relapse. Finally, clinicians must engage with the evolving discourse surrounding persistent symptoms, ensuring that management strategies are informed by current evidence and that patients are counseled appropriately on the anticipated trajectory of recovery, which for the vast majority is one of complete resolution without long-term cardiac sequelae when diagnosis and treatment are rendered in a timely and comprehensive fashion.<sup>14,15</sup>

### **DISCUSSION**

The discussion of Lyme carditis necessarily engages with the inherent tension between its characterization as a typically transient, antibiotic-responsive condition and the emerging clinical and scientific narratives that suggest a more heterogeneous and potentially lingering disease spectrum. On one hand, the established clinical paradigm is robust: the syndrome of early disseminated Lyme disease manifesting as a fluctuating atrioventricular block is well-described, diagnostically accessible through serology and electrocardiography, and effectively managed with targeted antimicrobials and temporary supportive care. The rapid resolution of high-grade block with antibiotics, obviating the need for permanent pacing in the vast majority of cases, stands as a testament to the primacy of active spirochetal infection and acute inflammation in its acute pathogenesis. This success reinforces the central tenet that timely recognition and eradication of the pathogen is the cornerstone of preventing catastrophic acute outcomes. However, this conventional framework is increasingly confronted by observations that challenge a purely binary model of infection and cure.

A primary point of discursive contention resides in the pathophysiological interpretation of symptoms that persist or newly arise following standard antibiotic treatment for documented Lyme carditis. While residual fatigue or subjective palpitations could be dismissed as non-specific or post-infectious asthenia, more objective findings, such as persistent, low-grade autonomic dysfunction or reproducible exercise-induced arrhythmias in previously affected individuals, invite deeper scrutiny. The traditional explanation attributes these phenomena to a "post-inflammatory" state or incidental findings. Yet, alternative hypotheses grounded in contemporary borrelia research warrant serious consideration. These include the potential for residual spirochetal antigens or degraded bacterial debris to perpetuate a localized immune response within cardiac tissue, a concept supported by models of persistent inflammation in

## **Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae**

other forms of infectious myocarditis. More provocatively, the possibility of viable, but difficult-to-culture, *Borrelia* persists evading antibiotic clearance and maintaining a low-grade antigenic stimulus presents a pathophysiological mechanism for chronicity, though direct histological evidence in human cardiac tissue remains elusive and controversial.

This discourse directly informs the clinical dilemma of defining therapeutic endpoints and managing the patient with so-called "post-treatment" symptoms. The absence of validated biomarkers for active cardiac inflammation or infection beyond the acute phase creates a diagnostic vacuum, often leaving clinicians to rely on symptom reports and non-specific testing. This uncertainty fuels debate regarding the utility and ethics of prolonged or repeated antibiotic courses in the absence of clear evidence of ongoing infection, a practice not supported by current guidelines and associated with significant risk. Conversely, dismissing all persistent symptoms risks overlooking a genuine, if poorly understood, organ-specific sequelae. This is where advanced imaging and electrophysiological studies may assume a more prominent role in future management, shifting the discussion from a purely serological one to a functional assessment of cardiac health.

Furthermore, the discussion must acknowledge the epidemiological evolution of the disease. As geographic ranges of vector ticks expand and public awareness grows, clinicians in non-endemic areas will encounter this condition with increasing frequency, potentially leading to under-diagnosis or over-diagnosis. This underscores the need for diagnostic algorithms that are both sensitive and specific, integrating travel history and advanced molecular testing methods that are currently primarily research tools. Ultimately, the discussion surrounding Lyme carditis is evolving from a focus on its acute management—a largely solved clinical problem—to a more nuanced engagement with its place within the broader spectrum of Lyme borreliosis. It compels the medical community to reconcile its straightforward acute treatment success with the complex, patient-driven reports of chronicity, urging a research agenda that prioritizes longitudinal cardiac studies, the development of novel diagnostic biomarkers for active cardiac involvement, and a deeper mechanistic understanding of host-pathogen interactions that may extend well beyond microbiological cure. This balanced perspective is essential to provide comprehensive care, maintain scientific rigor, and address the legitimate concerns of a patient population for whom the resolution of high-grade block may not equate to a complete return to pre-morbid cardiac well-being.

### **CONCLUSION**

Lyme carditis stands as a compelling exemplar of how a systemic infectious process can manifest with profound and specific organ pathology, in this case targeting the delicate

electrophysiological infrastructure of the heart. The synthesis of contemporary evidence affirms that its clinical identity is primarily defined by an acute, often labile, disturbance of atrioventricular conduction, arising within a distinct temporal window following *Borrelia burgdorferi* dissemination. The pathophysiological narrative has evolved from a simplistic model of direct spirochetal invasion to a more intricate understanding that incorporates a vigorous host-derived inflammatory response within the cardiac interstitium, potentially amplified by mechanisms of molecular mimicry and persistent immunological stimulation. This refined pathobiological framework is crucial, as it not only explains the characteristic fluctuating block but also provides a plausible substrate for the spectrum of disease, from subclinical electrical instability to fulminant myopericarditis. From a diagnostic standpoint, the enduring principle remains the necessity for a high clinical index of suspicion, particularly in endemic regions, where the presentation of new-onset heart block in a young individual should invariably prompt consideration of this entity. Diagnosis is fundamentally a syndromic construct, reliant upon the integration of a compatible clinical presentation, supportive serological evidence, and demonstrable cardiac involvement, most sensitively captured through continuous electrocardiographic monitoring. While advanced imaging, particularly cardiac magnetic resonance, offers invaluable tissue characterization, it serves as a complementary rather than a primary diagnostic tool. Therapeutically, the paradigm is gratifyingly effective, anchored by timely administration of appropriate antibiotic regimens, ranging from oral doxycycline for milder cases to intravenous ceftriaxone for significant conduction disease, coupled with vigilant cardiac monitoring and the judicious, temporary use of transvenous pacing for hemodynamic support. The near-universal reversibility of conduction abnormalities with antimicrobial therapy remains a hallmark distinguishing it from degenerative conductive pathologies.

Looking forward, the principal challenges and avenues for future research are crystallizing around the long-term implications of this inflammatory cardiac insult. While the majority of patients experience complete resolution, persistent clinical questions regarding potential subclinical electrical remodeling, the nature of post-infectious subjective symptoms, and the validity of conceptual models involving low-grade persistent inflammation or post-treatment immunologic dysregulation demand rigorous longitudinal study. The continued refinement of diagnostic biomarkers capable of distinguishing active infection from immunologic sequelae would represent a significant advance. Ultimately, the management of Lyme carditis epitomizes a success story in the treatment of infectious carditis when approached with informed clinical vigilance. However, it also serves as a reminder of the complex and sometimes protracted dialogue between pathogen and host, underscoring the imperative for

# Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae

ongoing research to fully elucidate the chronicity and totality of its impact on cardiac health, thereby ensuring optimal patient outcomes across the entire continuum of this disease.

## REFERENCES

- I. Radolf, J.D.; Strle, K.; Lemieux, J.E.; Strle, F. Lyme Disease in Humans. *Curr. Issues Mol. Biol.* 2021, 42, 333–384.
- II. Trevisan, G.; Cinco, M.; Trevisini, S.; di Meo, N.; Chersi, K.; Ruscio, M.; Forgiione, P.; Bonin, S. Borreliae Part 1: Borrelia Lyme Group and Echidna-Reptile Group. *Biology* 2021, 10, 1036.
- III. Pritt, B.S.; Mead, P.S.; Johnson, D.K.H.; Neitzel, D.F.; Respcio-Kingry, L.B.; Davis, J.P.; Schiffman, E.; Sloan, L.M.; Schriefer, M.E.; Replogle, A.J.; et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: A descriptive study. *Lancet Infect. Dis.* 2016, 16, 556–564.
- IV. Steere, A.C.; Strle, F.; Wormser, G.P.; Hu, L.T.; Branda, J.A.; Hovius, J.W.; Li, X.; Mead, P.S. Lyme borreliosis. *Nat. Rev. Dis. Primers* 2016, 2, 16090.
- V. Rollend, L.; Fish, D.; Childs, J.E. Transovarial transmission of Borrelia spirochetes by Ixodes scapularis: A summary of the literature and recent observations. *Ticks Tick Borne Dis.* 2013, 4, 46–51.
- VI. Radolf, J.D.; Caimano, M.J.; Stevenson, B.; Hu, L.T. Of ticks, mice and men: Understanding the dual-host lifestyle of Lyme disease spirochaetes. *Nat. Rev. Microbiol.* 2012, 10, 87–99.
- VII. Scheffold, N.; Herkommer, B.; Kandolf, R.; May, A.E. Lyme carditis—Diagnosis, treatment and prognosis. *Deutsches Ärzteblatt International* 2015, 112, 202–208.
- VIII. Kugeler, K.J.; Schwartz, A.M.; Delorey, M.J.; Mead, P.S.; Hinckley, A.F. Estimating the Frequency of Lyme Disease Diagnoses, United States, 2010–2018. *Emerg. Infect. Dis.* 2021, 27, 616–619.
- IX. Fish, A.E.; Pride, Y.B.; Pinto, D.S. Lyme carditis. *Infect. Dis. Clin. N. Am.* 2008, 22, 275–288.
- X. Forrester, J.D.; Meiman, J.; Mullins, J.; Nelson, R.; Ertel, S.H.; Cartter, M.; Brown, C.M.; Lijewski, V.; Schiffman, E.; Neitzel, D.; et al. Notes from the field: Update on Lyme carditis, groups at high risk, and frequency of associated sudden cardiac death—United States. *MMWR Morb. Mortal. Wkly. Rep.* 2014, 63, 982–983.
- XI. Kostic, T.; Momcilovic, S.; Perisic, Z.D.; Apostolovic, S.R.; Cvetkovic, J.; Jovanovic, A.; Barac, A.; Salinger-Martinovic, S.; Tasic-Otasevic, S. Manifestations of Lyme carditis. *Int. J. Cardiol.* 2017, 232, 24–32.
- XII. Linden, H. Lyme Carditis. Available online: <https://www.uptodate.com/contents/lyme-carditis>
- XIII. O’Connell, S.; Granström, M.; Gray, J.S.; Stanek, G. Epidemiology of European Lyme borreliosis. *Zentralblatt für Bakteriologie* 1998, 287, 229–240.
- XIV. Lantos, P.M.; Rumbaugh, J.; Bockenstedt, L.K.; Falck-Ytter, Y.T.; Aguero-Rosenfeld, M.E.; Auwaerter, P.G.; Baldwin, K.; Bannuru, R.R.; Belani, K.K.; Bowie, W.R.; et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. *Clin. Infect. Dis.* 2021, 72, e1–e48.
- XV. Shapiro, E.D.; Wormser, G.P. Lyme Disease in 2018: What Is New (and What Is Not). *JAMA* 2018, 320, 635–636.
- XVI. Schwartz A.M., Hinckley A.F., Mead P.S., Hook S.A., Kugeler K.J. Surveillance for Lyme Disease—United States, 2008–2015. *MMWR Surveill. Summ.* 2017;66:1–12. doi: 10.15585/mmwr.ss6622a1.
- XVII. Van der Linde M.R. Lyme carditis: Clinical characteristics of 105 cases. *Scand. J. Infect. Dis. Suppl.* 1991;77:81–84.
- XVIII. Caine J.A., Coburn J. A short-term Borrelia burgdorferi infection model identifies tissue tropisms and bloodstream survival conferred by adhesion proteins. *Infect. Immun.* 2015;83:3184–3194. doi: 10.1128/IAI.00349-15
- XIX. Brown E.L., Wooten R.M., Johnson B.J., Iozzo R.V., Smith A., Dolan M.C., Guo B.P., Weis J.J., Höök M. Resistance to Lyme disease in decorin-deficient mice. *J. Clin. Investig.* 2001;107:845–852. doi: 10.1172/JCI11692.
- XX. Lin Y.P., Benoit V., Yang X., Martinez-Herranz R., Pal U., Leong J.M. Strain-specific variation of the decorin-binding adhesin DbpA influences the tissue tropism of the lyme disease spirochete. *PLoS Pathog.* 2014;10:e1004238. doi: 10.1371/journal.ppat.1004238.
- XXI. Liang F.T., Brown E.L., Wang T., Iozzo R.V., Fikrig E. Protective niche for Borrelia burgdorferi to evade humoral immunity. *Am. J. Pathol.* 2004;165:977–985. doi: 10.1016/S0002-9440(10)63359-7.
- XXII. Weening E.H., Parveen N., Trzeciakowski J.P., Leong J.M., Höök M., Skare J.T. Borrelia burgdorferi lacking DbpBA exhibits an early survival defect during experimental infection. *Infect. Immun.* 2008;76:5694–5705. doi: 10.1128/IAI.00690-08.

**Lyme Borreliosis-Associated Carditis: Contemporary Perspectives on Pathogenesis, Clinical Manifestations, And Evolving Management Paradigms in the Context of Persistent Immunological Sequelae**

- XXIII. Koning J., Hoogkamp-Korstanje J.A., van der Linde M.R., Crijns H.J. Demonstration of spirochetes in cardiac biopsies of patients with Lyme disease. *J. Infect. Dis.* 1989;160:150–153. doi: 10.1093/infdis/160.1.150.
- XXIV. Yeung C., Baranchuk A. Diagnosis and Treatment of Lyme Carditis: JACC Review Topic of the Week. *J. Am. Coll. Cardiol.* 2019;73:717–726. doi: 10.1016/j.jacc.2018.11.035.
- XXV. Cadavid D., Bai Y., Hodzic E., Narayan K., Barthold S.W., Pachner A.R. Cardiac involvement in non-human primates infected with the Lyme disease spirochete *Borrelia burgdorferi*. *Lab. Invest.* 2004;84:1439–1450. doi: 10.1038/labinvest.3700177.
- XXVI. Saba S., VanderBrink B.A., Perides G., Glickstein L.J., Link M.S., Homoud M.K., Bronson R.T., Estes M., III, Wang P.J. Cardiac conduction abnormalities in a mouse model of Lyme borreliosis. *J. Interv. Card. Electrophysiol.* 2001;5:137–143. doi: 10.1023/A:1011469223042